Literature DB >> 22688581

Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer.

Kohei Hashimoto1, Hirohisa Horinouchi, Takashi Ohtsuka, Mitsutomo Kohno, Yotaro Izumi, Yuichiro Hayashi, Hiroaki Nomori.   

Abstract

Salvage surgery after gefitinib therapy in a 66-year-old female with cT4N1M1a lung adenocarcinoma in the right middle lobe, which had gene mutation of epidermal growth factor receptor, is presented. The patient had bulky hilar lymph nodes, pleural dissemination, and pulmonary metastases in the ipsilateral lobes. After 3 courses of chemotherapy, the patient was treated with gefitinib, resulting in partial response, i.e. only the primary tumor and the middle lobe atelectasis remained. We performed the middle lobe lobectomy aimed at local control and pathological confirmation of the remaining tumor. Because the hilum of the middle lobe was occupied with scar tissue, its pulmonary vein had to be cut within the pericardium and its pulmonary artery and bronchus had to be transected simultaneously with a stapler. Pathological stage was yp-T2aN0N0 with Ef 2. For salvage surgery after good response to gefitinib therapy, it should be taken care to expose pulmonary vessels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22688581     DOI: 10.1007/s11748-012-0087-2

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  7 in total

1.  Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.

Authors:  Tomoyuki Hishida; Kanji Nagai; Tetsuya Mitsudomi; Kohei Yokoi; Haruhiko Kondo; Hirohisa Horinouchi; Hirohiko Akiyama; Takeshi Nagayasu; Masahiro Tsuboi
Journal:  J Thorac Cardiovasc Surg       Date:  2010-08-02       Impact factor: 5.209

2.  Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

Authors:  Sae-Won Han; Tae-You Kim; Pil Gyu Hwang; Soohyun Jeong; Jeongmi Kim; In Sil Choi; Do-Youn Oh; Jee Hyun Kim; Dong-Wan Kim; Doo Hyun Chung; Seock-Ah Im; Young Tae Kim; Jong Seok Lee; Dae Seog Heo; Yung-Jue Bang; Noe Kyeong Kim
Journal:  J Clin Oncol       Date:  2005-02-14       Impact factor: 44.544

3.  Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.

Authors:  Humberto Lara-Guerra; Thomas K Waddell; Maria A Salvarrey; Anthony M Joshua; Catherine T Chung; Narinder Paul; Scott Boerner; Akira Sakurada; Olga Ludkovski; Clement Ma; Jeremy Squire; Geoffrey Liu; Frances A Shepherd; Ming-Sound Tsao; Natasha B Leighl
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

4.  Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

Authors:  Akira Inoue; Takuji Suzuki; Tatsuro Fukuhara; Makoto Maemondo; Yuichiro Kimura; Naoto Morikawa; Hiroshi Watanabe; Yasuo Saijo; Toshihiro Nukiwa
Journal:  J Clin Oncol       Date:  2006-06-19       Impact factor: 44.544

5.  Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.

Authors:  N C Choi; R W Carey; W Daly; D Mathisen; J Wain; C Wright; T Lynch; M Grossbard; H Grillo
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Authors:  Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox
Journal:  Lancet       Date:  2009-07-24       Impact factor: 79.321

7.  Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.

Authors:  Kazuya Takamochi; Kazuya Suzuki; Haruhiko Sugimura; Kazuhito Funai; Hiroki Mori; Abul Hasan Muhammad Bashar; Teruhisa Kazui
Journal:  Lung Cancer       Date:  2007-06-04       Impact factor: 5.705

  7 in total
  3 in total

Review 1.  Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.

Authors:  Yoko Yamamoto; Ken Kodama; Tomohiro Maniwa; Masashi Takeda
Journal:  J Cardiothorac Surg       Date:  2017-11-23       Impact factor: 1.637

2.  Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series.

Authors:  Weian Song; Shouyin Di; Junqiang Liu; Boshi Fan; Jiahua Zhao; Shaohua Zhou; Siyu Chen; Hai Dong; Caiying Yue; Taiqian Gong
Journal:  Thorac Cancer       Date:  2020-02-28       Impact factor: 3.500

3.  Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment.

Authors:  Yasuhiro Chikaishi; Hidetaka Uramoto; Soichi Oka; Shuya Nagata; Hidehiko Shimokawa; Tomoko So; Sohsuke Yamada; Takeshi Hanagiri; Hiroshi Mukae; Fumihiro Tanaka
Journal:  Case Rep Oncol       Date:  2014-02-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.